Clinical Predictors and Outcomes of Consistent Bronchodilator Response in the Childhood Asthma Management Program

Overview

Journal J Allergy Clin Immunol

Specialty Allergy & Immunology

Date 2008 Oct 14

PMID 18848350

Citations 32

Authors

Sunita Sharma

Augusto A Litonjua

Kelan G Tantisira

Anne L Fuhlbrigge

Stanley J Szefler

Robert C Strunk

Robert S Zeiger

Amy J Murphy

Scott T Weiss

Affiliations

Soon will be listed here.

Abstract

Background: Among asthmatic subjects, bronchodilator response (BDR) to inhaled beta(2)-adrenergic agonists is variable, and the significance of a consistent response over time is unknown.

Objective: We assessed baseline clinical variables and determined the clinical outcomes associated with a consistently positive BDR over 4 years in children with mild-to-moderate persistent asthma.

Methods: In the 1041 participants in the Childhood Asthma Management Program, subjects with a change in FEV(1) of 12% or greater (and 200 mL) after inhaled beta(2)-agonist administration at each of their yearly follow-up visits (consistent BDR) were compared with those who did not have a consistent BDR.

Results: We identified 52 children with consistent BDRs over the 4-year trial. Multivariable logistic regression modeling demonstrated that lower baseline prebronchodilator FEV(1) values (odds ratio, 0.71; P < .0001), higher log10 IgE levels (odds ratio, 1.97; P = .002), and lack of treatment with inhaled corticosteroids (odds ratio, 0.31; P = .009) were associated with a consistent BDR. Individuals who had a consistent BDR had more hospital visits (P = .007), required more prednisone bursts (P = .0007), had increased nocturnal awakenings caused by asthma (P < .0001), and missed more days of school (P = .03) than nonresponders during the 4-year follow-up.

Conclusions: We have identified predictors of consistent BDR and determined that this phenotype is associated with poor clinical outcomes.

Citing Articles

Effects of the salbutamol bronchodilator response on measurements of fractional exhaled nitric oxide in children with asthma: a prospective, observational study.

Wu P, Liu Y, Chen C, Chen F, Jiang W, Zhao S Transl Pediatr. 2022; 11(10):1624-1632.

PMID: 36345444 PMC: 9636456. DOI: 10.21037/tp-22-398.

Genome-wide association study in minority children with asthma implicates DNAH5 in bronchodilator responsiveness.

Joo J, Mak A, Xiao S, Sleiman P, Hu D, Huntsman S Sci Rep. 2022; 12(1):12514.

PMID: 35869121 PMC: 9307508. DOI: 10.1038/s41598-022-16488-6.

Bronchodilator Dose Responsiveness in Children and Adolescents: Clinical Features and Association with Future Asthma Exacerbations.

Grunwell J, Nguyen K, Bruce A, Fitzpatrick A J Allergy Clin Immunol Pract. 2019; 8(3):953-964.

PMID: 31614217 PMC: 7064424. DOI: 10.1016/j.jaip.2019.09.033.

Differential long-term regulation of TAS2R14 by structurally distinct agonists.

Woo J, Castano M, Goss A, Kim D, Lewandowski E, Chen Y FASEB J. 2019; 33(11):12213-12225.

PMID: 31430434 PMC: 6902689. DOI: 10.1096/fj.201802627RR.

Clinical significance of the bronchodilator response in children with severe asthma.

Coverstone A, Bacharier L, Wilson B, Fitzpatrick A, Teague W, Phipatanakul W Pediatr Pulmonol. 2019; 54(11):1694-1703.

PMID: 31424170 PMC: 7015037. DOI: 10.1002/ppul.24473.

References

Zeiger R, Szefler S, Phillips B, Schatz M, Martinez F, Chinchilli V . Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol. 2006; 117(1):45-52. DOI: 10.1016/j.jaci.2005.10.012. View

Drazen J, Silverman E, Lee T . Heterogeneity of therapeutic responses in asthma. Br Med Bull. 2001; 56(4):1054-70. DOI: 10.1258/0007142001903535. View

OByrne P, Parameswaran K . Pharmacological management of mild or moderate persistent asthma. Lancet. 2006; 368(9537):794-803. DOI: 10.1016/S0140-6736(06)69289-1. View

Weiss S, Litonjua A, Lange C, Lazarus R, Liggett S, Bleecker E . Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics J. 2006; 6(5):311-26. DOI: 10.1038/sj.tpj.6500387. View

Sorkness C, Lemanske Jr R, Mauger D, Boehmer S, Chinchilli V, Martinez F . Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol. 2006; 119(1):64-72. DOI: 10.1016/j.jaci.2006.09.042. View

Martin R, Szefler S, King T, Kraft M, Boushey H, Chinchilli V . The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J Allergy Clin Immunol. 2007; 119(1):73-80. PMC: 2872157. DOI: 10.1016/j.jaci.2006.10.035. View

Deykin A, Wechsler M, Boushey H, Chinchilli V, Kunselman S, Craig T . Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med. 2006; 175(3):228-34. PMC: 1899264. DOI: 10.1164/rccm.200601-112OC. View

Bousquet J, Clark T, Hurd S, Khaltaev N, Lenfant C, OByrne P . GINA guidelines on asthma and beyond. Allergy. 2007; 62(2):102-12. DOI: 10.1111/j.1398-9995.2006.01305.x. View

Beydon N, MBuila C, Bados A, Peiffer C, Bernard A, Zaccaria I . Interrupter resistance short-term repeatability and bronchodilator response in preschool children. Respir Med. 2007; 101(12):2482-7. DOI: 10.1016/j.rmed.2007.07.005. View

10.

Eliasson O, DEGRAFF Jr A . The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Influence of clinical diagnosis, spirometric, and anthropometric variables. Am Rev Respir Dis. 1985; 132(4):858-64. DOI: 10.1164/arrd.1985.132.4.858. View

11.

Litonjua A, Silverman E, Tantisira K, Sparrow D, Sylvia J, Weiss S . Beta 2-adrenergic receptor polymorphisms and haplotypes are associated with airways hyperresponsiveness among nonsmoking men. Chest. 2004; 126(1):66-74. DOI: 10.1378/chest.126.1.66. View

12.

Masoli M, Fabian D, Holt S, Beasley R . The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004; 59(5):469-78. DOI: 10.1111/j.1398-9995.2004.00526.x. View

13.

Abramson M, Walters J, Walters E . Adverse effects of beta-agonists: are they clinically relevant?. Am J Respir Med. 2004; 2(4):287-97. DOI: 10.1007/BF03256657. View

14.

Xu X, Weiss S . Familial aggregation of bronchodilator response: a community-based study. Am J Respir Crit Care Med. 2002; 166(5):774. View

15.

Raby B, Weiss S . Beta2-adrenergic receptor genetics. Curr Opin Mol Ther. 2002; 3(6):554-66. View

16.

Szefler S, Weiss S, Tonascia J, Adkinson N, Bender B, Cherniack R . Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000; 343(15):1054-63. DOI: 10.1056/NEJM200010123431501. View

17.

Pellegrino R, Viegi G, Brusasco V, Crapo R, Burgos F, Casaburi R . Interpretative strategies for lung function tests. Eur Respir J. 2005; 26(5):948-68. DOI: 10.1183/09031936.05.00035205. View

18.

Tantisira K, Weiss S . The pharmacogenetics of asthma: an update. Curr Opin Mol Ther. 2005; 7(3):209-17. View

19.

Szefler S, Phillips B, Martinez F, Chinchilli V, Lemanske R, Strunk R . Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005; 115(2):233-42. DOI: 10.1016/j.jaci.2004.11.014. View

20.

Kitch B, Paltiel A, M Kuntz K, Dockery D, Schouten J, Weiss S . A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest. 2004; 126(6):1875-82. DOI: 10.1378/chest.126.6.1875. View